tirzepatide death AHA 2024 - lowers the risk of worsening heart failure and CVD for obese adults Tirzepatide linked to lower risk

Cost concerns appear frequently

SOUL: CVOT 13 Study design: A randomized, international, double-blind, parallel-group, placebo-controlled, event-driven, superiority phase 3b trial in adults with T2D and established atherosclerotic cardiovascular disease, CKD, or both

Always coordinate any change with a prescriber

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become common therapies in the management of chronic conditions such as diabetes and obesity

Pharmacies willing to provide COAs on request demonstrate transparency and accountability

So, Mounjaro unlike Wegovy has glucose-dependent insulinotropic Polypeptide (GIP) in addition to Glucagon-Like Peptide-1 (GLP-1)